![Martin Murphy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin Murphy
Directeur/Membre du Conseil chez
SYNAIRGEN PLC
Fortune : - $ au 30/06/2026
Profil
Martin Patrick Murphy is the founder of Syncona Partners LLP, founded in 2012, holding the title of Chairman since 2023.
Dr. Murphy is also the founder of Syncona Ltd...
Current positions include Chief Executive Officer at Syncona LLP; Chairman at Autolus Ltd. since 2021; Chairman at Blue Earth Diagnostics Ltd.; Director at Pulmagen Therapeutics (Synergy) Ltd.; Director at Biomodal Ltd.; Independent Non-Executive Director at Synairgen Plc starting 2025; Independent Director at Century Therapeutics, Inc. starting 2025.
Former positions include Chairman at Serentis Ltd., Vantia Ltd., Azeria Therapeutics Ltd., and Anaveon AG (2019–2024, Chairman-Supervisory Board); Chairman at Syncona Investment Management Ltd. (2017–2023); Director at Momenta Pharmaceuticals, Inc., Oxxon Therapeutics, Inc., Healthcare Brands International Ltd., PregLem SA, Nxera Pharma UK Ltd., Xention Ltd., Quell Therapeutics Ltd., Neogene Therapeutics, Inc., Syncona Discovery Ltd., Resolution Therapeutics Ltd., Clade Therapeutics, Inc.; Non-Executive Director at Pulmagen Therapeutics (Synergy) Ltd., Autolus Therapeutics Plc (2021–2025), Achilles Therapeutics Plc, Achilles Therapeutics UK Ltd.; Principal at 3i Group Plc; Partner at MVM Partners LLP (2002–2012); Member-Healthcare Investment Team at 3i Plc; Engagement Manager at McKinsey & Co., Inc. (United Kingdom).
Education includes undergraduate and graduate degrees from the University of Oxford and a doctorate from the University of Cambridge conferred in 1994.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2025 | 0 ( -.--% ) | - $ | 30/06/2026 | |
| 11/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Postes actifs de Martin Murphy
| Sociétés | Poste | Début |
|---|---|---|
| SYNAIRGEN PLC | Directeur/Membre du Conseil | 16/01/2025 |
| CENTURY THERAPEUTICS, INC. | Directeur/Membre du Conseil | 09/12/2025 |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Provides biopharmaceutical services | Président | 01/04/2021 |
Syncona LLP
 Syncona LLP Financial ConglomeratesFinance Operates as a healthcare investment company | Directeur Général | - |
Blue Earth Diagnostics Ltd.
 Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Develops and commercialization molecular imaging technologies | Président | - |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Directeur Général | 01/05/2012 |
Biomodal Ltd.
 Biomodal Ltd. Miscellaneous Commercial ServicesCommercial Services Provides epigenetic tools | Directeur/Membre du Conseil | - |
Pulmagen Therapeutics (Synergy) Ltd.
 Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Develops therapeutics for respiratory diseases | Directeur/Membre du Conseil | 06/09/2011 |
Anciens postes connus de Martin Murphy
| Sociétés | Poste | Fin |
|---|---|---|
| AUTOLUS THERAPEUTICS PLC | Président | 15/09/2021 |
| ░░░░░░░ ░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Formation de Martin Murphy
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
80
Relations au 1er degré
34
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 34 |
|---|---|
3i Group Plc
 3i Group Plc Investment Trusts/Mutual FundsMiscellaneous Functions as a closed-end investment fund or Investment trust | Miscellaneous |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that discovers and develops novel biologic therapies for the treatment of rare immune-mediated diseases | Health Technology |
Synairgen Plc
 Synairgen Plc Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for respiratory disorders | Health Technology |
Syncona Ltd.
 Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MVM Partners LLP
 MVM Partners LLP Investment ManagersFinance MVM Partners invests in companies located across the globe. The firm focuses on healthcare and life sciences sectors. It provides financing for growth capital requirements with an investment size of USD 20 - 100 million. | Finance |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
3i Plc
 3i Plc Financial ConglomeratesFinance Private equity firm and provides investment advice | Finance |
Pulmagen Therapeutics (Synergy) Ltd.
Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Develops therapeutics for respiratory diseases | Commercial Services |
Oxxon Therapeutics, Inc.
 Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures antigen-specific immunotherapy’s to treat patients | Health Technology |
Healthcare Brands International Ltd.
 Healthcare Brands International Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
PregLem SA
 PregLem SA Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products specializing in gynecology and women's reproductive health | Health Technology |
Serentis Ltd.
 Serentis Ltd. Pharmaceuticals: MajorHealth Technology Discovers, develops and distributes pharmaceutical products | Health Technology |
Nxera Pharma UK Ltd.
 Nxera Pharma UK Ltd. Pharmaceuticals: MajorHealth Technology Designs and develops new medicines targeting G protein-coupled receptors | Health Technology |
Vantia Ltd.
 Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Provides molecule agonists of vasopressin receptors | Commercial Services |
McKinsey & Co., Inc. (United Kingdom)
 McKinsey & Co., Inc. (United Kingdom) Investment ManagersFinance Provides investment advisory services | Finance |
Xention Ltd.
 Xention Ltd. Pharmaceuticals: MajorHealth Technology Develops and researches drugs | Health Technology |
Biomodal Ltd.
Biomodal Ltd. Miscellaneous Commercial ServicesCommercial Services Provides epigenetic tools | Commercial Services |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Finance |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Provides biopharmaceutical services | Health Technology |
Blue Earth Diagnostics Ltd.
Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Develops and commercialization molecular imaging technologies | Health Services |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer | Health Technology |
Syncona LLP
Syncona LLP Financial ConglomeratesFinance Operates as a healthcare investment company | Finance |
Syncona Investment Management Ltd.
 Syncona Investment Management Ltd. Investment ManagersFinance Syncona aims to build a sustainable, diverse portfolio of 15-20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which they are seeking to deliver strong risk-adjusted returns for shareholders. The firm takes a long-term view, underpinned by a strategic capital base which enables them to maintain significant ownership positions in their companies and provides them with control and flexibility over the management of their portfolio. | Finance |
Autolus Therapeutics Plc
 Autolus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of gene therapies | Health Technology |
Azeria Therapeutics Ltd.
 Azeria Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops drugs for breast and prostate cancer | Health Technology |
Anaveon AG
 Anaveon AG BiotechnologyHealth Technology Develops biologics for cancer | Health Technology |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops and supplies immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases | Health Technology |
Neogene Therapeutics, Inc.
 Neogene Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company that provides TCR therapies targeting neo-antigens in solid cancers | Health Technology |
Century Therapeutics, Inc.
 Century Therapeutics, Inc. BiotechnologyHealth Technology Develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies | Health Technology |
Syncona Discovery Ltd.
 Syncona Discovery Ltd. Financial ConglomeratesFinance Provides investment services | Finance |
Resolution Therapeutics Ltd.
 Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and experimental development in biotechnology | Commercial Services |
Achilles Therapeutics Plc
 Achilles Therapeutics Plc Pharmaceuticals: MajorHealth Technology Develops and sells cancer immunotherapies | Health Technology |
Clade Therapeutics, Inc.
 Clade Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Choisissez Zonebourse 
